Venus Medtech (Hangzhou) Inc 2020 AR2
The report highlights Venus Medtech (Hangzhou) Inc.'s financial and operational performance for the fiscal year 2020, alongside its Environmental, Social, and Governance (ESG) practices. Despite the challenges of the COVID-19 pandemic, the company achieved an 18.3% year-on-year revenue increase to RMB 276 million, driven by its core transcatheter heart valve products. Key milestones included the NMPA approval of VenusA-Plus, China's first retrievable TAVR system, and the expansion of its global clinical trials. On the sustainability front, the company established its three-level ESG governance structure, implemented resource-saving measures, and maintained zero workplace fatalities.
Company: Venus Medtech (Hangzhou) Inc
Sector: Health Care
Country: China
Year: 2020
Type: AR2
Pages: 265
Venus Medtech (Hangzhou) Inc
Annual Report
The report highlights Venus Medtech (Hangzhou) Inc.'s financial and operational performance for the fiscal year 2020, alongside its Environmental, Social, and Governance (ESG) practices. Despite the challenges of the COVID-19 pandemic, the company achieved an 18.3% year-on-year revenue increase to RMB 276 million, driven by its core transcatheter heart valve products. Key milestones included the NMPA approval of VenusA-Plus, China's first retrievable TAVR system, and the expansion of its global clinical trials. On the sustainability front, the company established its three-level ESG governance structure, implemented resource-saving measures, and maintained zero workplace fatalities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Workplace Fatalities
Employees